Prescription Drug Expenditures, New Drug Launches, and Disease-specific Mortality
Abstract/Contents
- Abstract
- This paper explores the relationship between disease-level prescription drug expenditures, the availability of FDA-approved prescription drugs, disease-level scientific R&D expenses, and disease-specific mortality. Leveraging prescription drug data from the national Medical Expenditures Panel Survey, mortality data from the Center for Disease Control, research expenditures data from the NIH, and drug launch data from the FDA, I develop a number of fixed effects regression models to assess how movements in drug launches, disease-level research, and disease-level expenditures impact mortality as a health endpoint. This research elucidates how various movements in pharmaceutical innovation can predict changes in mortality rates. This paper also aims to understand the impact of new drug launches across time and resolve whether mortality trends are more significantly related to drug launches in a previous year than in a current year – the former of which suggests that drug launches drive movements in mortality rather than the reverse. Analysis of a time lagged innovation variable estimates that a 1% increase in the cumulative available prescription drugs on the market yields a 0.25% decrease in mortality rates for individuals above the age of 65 and a 0.37% decrease in mortality rate for individuals below the age of 65. Analysis of disease-level NIH R&D data shows that a 1% increase in research spending yields a 0.59% decrease in mortality rate for individuals older than 65.
Description
| Type of resource | text |
|---|---|
| Date created | May 2019 |
Creators/Contributors
| Author | Arulmani, Sruti |
|---|---|
| Degree granting institution | Stanford University, Department of Economics |
| Primary advisor | Duggan, Mark |
Subjects
| Subject | Department of Economics |
|---|---|
| Subject | pharmaceutical innovation |
| Subject | healthcare |
| Subject | drug expenditures |
| Subject | R&D |
| Subject | mortality |
| Subject | prescription drugs |
| Subject | drug prices |
| Genre | Thesis |
Bibliographic information
Access conditions
- Use and reproduction
- User agrees that, where applicable, content will not be used to identify or to otherwise infringe the privacy or confidentiality rights of individuals. Content distributed via the Stanford Digital Repository may be subject to additional license and use restrictions applied by the depositor.
- License
- This work is licensed under a Creative Commons Attribution Non Commercial 3.0 Unported license (CC BY-NC).
Preferred citation
- Preferred Citation
- Arulmani, Sruti. (2019). Prescription Drug Expenditures, New Drug Launches, and Disease-specific Mortality. Stanford Digital Repository. Available at: https://purl.stanford.edu/pp597wz6752
Collection
Stanford University, Department of Economics, Honors Theses
View other items in this collection in SearchWorksContact information
- Contact
- sruti.arulmani@gmail.com
Also listed in
Loading usage metrics...